Heparin-induced thrombocytopenia II-induced critical limb ischaemia treated with urokinase and argatroban

Jan Beyer; Kai Halbritter; Matthias Weise; Johannes Leonhard; Sebastian Schellong

doi:10.1160/TH06-11-0673

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2007; 98(02): 470-472
DOI: 10.1160/TH06-11-0673

Case Report

Schattauer GmbH

Heparin-induced thrombocytopenia II-induced critical limb ischaemia treated with urokinase and argatroban

Jan Beyer

¹Division of Vascular Medicine, Department of Medicine 3

,

Kai Halbritter

¹Division of Vascular Medicine, Department of Medicine 3

,

Matthias Weise

²Division of Intensive Care Medicine, Department of Medicine

,

Johannes Leonhard

³Department of Radiology, University Hospital “Carl Gustav Carus”, Technical University Dresden, Dresden, Germany

,

Sebastian Schellong

¹Division of Vascular Medicine, Department of Medicine 3

References
1 Greinacher A, Farner B, Kroll H. et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005; 94: 132-135.
2 Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 2006; 95: 967-981.
3 Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost 2005; 93: 999-1000.
4 Hursting MJ, Alford KL, Becker JC. et al. Novastan (brand of argatroban):a small molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997; 23: 503-516.
5 Warkentin TE, Greinacher A, Craven S. et al. Differences in the clinically effective molar concentrations of four direct thrombin in hibitors explain their variable prothrombin time prolongation. Thromb Haemost 2005; 94: 958-964.
6 Lewis BE, Wallis DE, Leya F. et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163: 1849-1856.
7 Lewis BE, Wallis DE, Berkowitz SD. et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838-1843.
8 Jang IK, Brown DF, Giugliano RP. et al. A multicentre, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (tPA) in acute myocardial infarction: myocardial infarction with novastan and tPA (MINT) study. J Am Coll Cardiol 1999; 33: 1880-1885.
9 Vermeer F, Vahanian A, Fels PW. et al. Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study. J Thromb Thrombolysis 2000; 10: 233-240.
10 Behar S, Hod H, Kaplinski E. Argatroban versus heparin as adjuvant therapy to thrombolysis for acute myocardial infarction: safety considerations-ARGAMI-2 Study. Circulation 1998; 98 (Suppl. 17) 1453-1454.
11 Lewis BE, Matthai Jr WH, Cohen M. et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cadiovasc Interv 2002; 57: 177-184.
12 Jang IK, Lewis BE, Matthai Jr WH. et al. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, non-randomized pilot study. J Thromb Thrombolysis 2004; 18: 31-37.
13 La Monte MP, Nash ML, Wang DZ. et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke 2004; 35: 1677-1682.
14 Sugg RM, Pary JK, Uchino K. et al. Argatroban tPA stroke study: study design and results in the first treated cohort. Arch Neurol 2006; 63: 1057-1062.
15 Sabatine MS, Tu TM, Jang IK. Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase. J Thromb Thrombolysis 2000; 10: 189-196.